| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.800 | GeneticVariation | BEFREE | The G84E variant was detected in 4 patients (prevalence 0.42%, 95% CI 0.12-1.08), of whom 3 had prostate cancer on biopsy. | 23036981 | 2013 |
||||
|
0.800 | GeneticVariation | BEFREE | The HOXB13 G84E mutation was identified in 0.49% of controls and in 2.51% of PCa cases. | 26779768 | 2016 |
||||
|
0.800 | GeneticVariation | BEFREE | The G84E mutation was more frequent among white case subjects than among white control subjects (10 of 1525 [0.7%] vs 2 of 1757 [0.1%], P = .01) and was associated with an increased risk of prostate cancer (unadjusted odds ratio = 5.8, 95% confidence interval = 1.3 to 26.5, P = .01). | 22781434 | 2012 |
||||
|
0.800 | GeneticVariation | BEFREE | G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis. | 24026887 | 2014 |
||||
|
0.800 | GeneticVariation | BEFREE | The clinical importance of HOXB13 G84E in PrCa management has not been established. | 25595936 | 2015 |
||||
|
0.800 | GeneticVariation | BEFREE | Additional genotyping, conditional regression and haplotype analyses indicated that the newly identified common variants tag a rare, partially correlated coding variant in the HOXB13 gene (G84E, rs138213197), which has been identified recently as a moderate penetrance PrCa susceptibility allele. | 24550738 | 2014 |
||||
|
0.800 | GeneticVariation | BEFREE | These findings demonstrate that the HOXB13 G84E mutation is present in ~5 % of prostate cancer families, predominantly of European descent, and confirm its association with prostate cancer risk. | 23064873 | 2013 |
||||
|
0.010 | GeneticVariation | BEFREE | Interplay of <i>HOXB13</i> (G84E) and <i>CIP2A</i> (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; <i>P</i> = 0.000024). | 30181389 | 2018 |